论文部分内容阅读
结核病的再度爆发和耐药结核分枝杆菌的出现,使结核病再次成为威胁人类健康的主要疾病之一。而在过去的40年里未开发出新型高效的抗结核药物。研究抗结核药物来有效地预防和治疗结核感染是非常必要的。目前世界范围内已经进入临床阶段的抗结核新药有莫西沙星、加替沙星、利福喷汀、利福拉齐及TMC207,PA-824,OPC-67683,SQ-109,LL3858等。文中分别介绍了这些新药的化学结构、作用机制、抗结核活性以及临床应用进展。
The re-emergence of tuberculosis and the emergence of drug-resistant Mycobacterium tuberculosis make tuberculosis once again become one of the major diseases that threaten human health. In the past 40 years, however, no new and highly effective anti-TB drugs have been developed. It is necessary to study anti-tuberculosis drugs to effectively prevent and treat TB infection. The new anti-TB drugs that have entered the clinical stage in the world are moxifloxacin, gatifloxacin, rifapentine, Rifalazil and TMC207, PA-824, OPC-67683, SQ-109 and LL3858. The article introduces the chemical structure, mechanism of action, anti-TB activity and clinical application progress of these new drugs respectively.